



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

July 24, 2025

Corporate Relationship Department
M/s. BSE Ltd.
Dalal Street, Fort
Mumbai 400 001

Manager – Listing
M/s. National Stock Exchange of India Ltd
“Exchange Plaza”, Bandra – Kurla Complex
Bandra (E) **Mumbai 400 051**

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Ref: Our earlier intimation letter dated June 13, 2025

With reference to the above cited subject, please find enclosed herewith the Press Release on the U.S. Food and Drug Administration (FDA) inspection at the API manufacturing plant located in Mekaguda, Hyderabad, India.

This is for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

NATCO Pharma Limited, API unit in Mekaguda Receives Establishment Inspection Report (EIR) from U.S. FDA

Ref: Our letter dated June 13th 2025

Hyderabad, India, July 24rd, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") we hereby inform you that the U.S. Food and Drug Administration (FDA) had conducted an inspection at the Active Pharmaceutical Ingredient Division located in Mekaguda, Hyderabad, India, from June 9th – June 13th, 2025. The Company received 1 (One) observation in the Form-483 which was classified as "Voluntary Action Indicated" (VAI).

In connection with the above we inform you that the U.S. FDA has now issued EIR for the API facility located in Mekaguda on July 24th 2025.

Please take the above information on record.

About NATCO Pharma Limited

NATCO Pharma Limited, (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's different manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com.

For further information or queries please contact:

Rajeev Menon – Manager, Investor Relations
Email: r.menon@natcopharma.co.in

Rajesh Chebiyam – EVP, Crop Health Sciences
Email: investors@natcopharma.co.in